Clinical Trials
7 trialsNCT03367247 2026-03-10
BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and Renewal
Dana-Farber Cancer Institute
Phase NA Completed
NCT05001347 2025-12-16
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
I-Mab Biopharma US Limited
Phase 2 Completed
NCT04644315 2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2 Terminated
NCT03989115 2023-06-26
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Revolution Medicines, Inc.
Phase 1/2 Completed
NCT00390182 2020-03-18
GCC0319
University of Maryland, Baltimore
Phase 1/2 Completed
NCT03300843 2019-12-13
Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02417753 2017-05-15
AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated